Strata seeks CMS temporary codes for expanded XTRAC reimbursement; triples addressable market to 30M+

STRATA Skin Sciences, Inc.

Working with CMS to secure temporary codes for expanded CPT codes for XTRAC, aiming for 2026 reimbursement instead of 2027.
Expanded coding triples addressable patient population to over 30M for inflammatory and autoimmune skin conditions.
Two new studies show excimer laser plus JAK inhibitors safe and effective for vitiligo, supporting XTRAC use.
Federal court adds LaserOptek Korea and C. Dalton as defendants in false advertising lawsuit; STRATA encouraged by ruling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.